Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
John Foerster, Aleksandra Molęda
doaj +4 more sources
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid [PDF]
Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230.
Fangyuan Chen +4 more
doaj +2 more sources
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis [PDF]
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj +2 more sources
Interleukin 13 Promotes Maturation and Proliferation in Metaplastic GastroidsSummary [PDF]
Background & Aims: Type 2 innate lymphoid cells (ILC2s) and interleukin-13 (IL-13) promote the onset of spasmolytic polypeptide-expressing metaplasia (SPEM) cells. However, little is known about molecular effects of IL-13 in SPEM cells. We now sought
Ela W. Contreras-Panta +8 more
doaj +2 more sources
Association of interleukin-13 gene single nucleotide polymorphism rs1800925 with allergic asthma in Asian population: A meta-analysis [PDF]
Kenneth V. Gaceja +5 more
openalex +2 more sources
Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data [PDF]
Emi Sato +4 more
openalex +2 more sources
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient.
Yoshihito Shima
doaj +1 more source
Characterization of the Interaction between Interleukin-13 and Interleukin-13 Receptors [PDF]
Interleukin-13 (IL-13) possesses two types of receptor: the heterodimer, composed of the IL-13Ralpha1 chain (IL-13Ralpha1) and the IL-4Ralpha chain (IL-4Ralpha), transducing the IL-13 signals; and the IL-13Ralpha2 chain (IL-13Ralpha2), acting as a nonsignaling "decoy" receptor.
Kazuhiko, Arima +8 more
openaire +2 more sources
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves +2 more
doaj +1 more source
Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis
BackgroundFibrostenotic disease is a common complication in Crohn’s disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall.
Kristina Koop +19 more
doaj +1 more source

